US 11,840,566 B2
Methods of treating asthma with polypeptides targeting IL-13 and TSLP
Heidi Rommelaere, Ghent (BE); Ann Brigé, Ertvelde (BE); Sigrid Cornelis, St. Martens-Latem (BE); Bruno Dombrecht, Heusden (BE); Eric Lorent, Zwijnaarde (BE); Melanie Rieger, Zwijnaarde (BE); Timothy Soos, Bridgewater, NJ (US); John Park, Warthausen (DE); Bernd Weigle, Ingelheim am Rhein (DE); and Klaus Erb, Ingelheim am Rhein (DE)
Assigned to Ablynx N.V., Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed by Ablynx N.V., Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed on Nov. 19, 2021, as Appl. No. 17/530,800.
Application 17/530,800 is a division of application No. 17/208,046, filed on Mar. 22, 2021, granted, now 11,208,476.
Application 17/208,046 is a continuation of application No. 17/115,906, filed on Dec. 9, 2020, abandoned.
Claims priority of provisional application 62/945,391, filed on Dec. 9, 2019.
Claims priority of application No. 20305064 (EP), filed on Jan. 27, 2020.
Prior Publication US 2022/0177565 A1, Jun. 9, 2022
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 2317/565 (2013.01)] 18 Claims
 
1. A method of treating asthma, wherein said method comprises administering, to a subject in need thereof, an effective amount of a polypeptide that comprises at least one immunoglobulin single variable domain (ISVD) that specifically binds to IL13 or TSLP, wherein said ISVD comprises three complementarity determining regions (CDR1 to CDR3, respectively); and wherein the at least one ISVD comprises:
a) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,
b) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,
c) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, or
d) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21.